Leukemoid Reaction
Leukocyte Count
Paraneoplastic Syndromes
Thrombocythemia, Essential
Polycythemia Vera
Myeloproliferative Disorders
Granulocyte Colony-Stimulating Factor
Anemia, Myelophthisic
Leukocytes
Selectins
Diverticulitis, Colonic
Fatal Outcome
Bordetella pertussis
Neutrophils
Primary Myelofibrosis
Sweet Syndrome
Oxides
A murine model of renal abscess formation. (1/489)
We developed a murine model of kidney abscess by direct renal injection of either Escherichia coli (1 x 10(6) to 7 x 10(6) organisms) or sterile medium. Bacterial infection produced renal abscesses, bacteremia, and late-onset leukocytosis in all animals. Controls were unaffected. This model may be useful for the study of various sequelae of kidney infection. (+info)Effects of interleukin-1 receptor antagonist overexpression on infection by Listeria monocytogenes. (2/489)
Interleukin-1 receptor antagonist (IL-1ra) is a naturally occurring cytokine whose only known function is the inhibition of interleukin-1 (IL-1). Using a reverse genetic approach in mice, we previously showed that increasing IL-1ra gene dosage leads to reduced survival of a primary listerial infection. In this study, we characterize further the role of endogenously produced IL-1ra and, by inference, IL-1 in murine listeriosis. IL-1ra overexpression inhibits, but does not eliminate, primary immune responses, reducing survival and increasing bacterial loads in the target organs. We demonstrate that IL-1ra functions in the innate immune response to regulate the peak leukocyte levels in the blood, the accumulation of leukocytes at sites of infection, and the activation of macrophages during a primary infection. Reduced macrophage class II major histocompatibility complex expression was observed despite increased gamma interferon (IFN-gamma) levels, suggesting that IL-1 activity is essential along with IFN-gamma for macrophage activation in vivo. We also show that IL-1ra plays a more limited role during secondary listeriosis, blunting the strength of the delayed-type hypersensitivity response to listerial antigen while not significantly altering cellular immunity to a second infectious challenge. When these results are compared to those for other mutant mice, IL-1ra appears to be unique among the cytokines studied to date in its regulation of leukocyte migration during primary listeriosis. (+info)Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. (3/489)
The pathogenesis of tuberculous meningitis, a devastating complication of tuberculosis in man, is poorly understood. We previously reported that rabbits with experimental tuberculous meningitis were protected from death by a combination of antibiotics and thalidomide therapy. Survival was associated with inhibition of tumor necrosis factor alpha (TNF-alpha) production by thalidomide. To test whether cerebrospinal fluid (CSF) levels of TNF-alpha correlated with pathogenesis, the response of rabbits infected in the central nervous system (CNS) with various mycobacterial strains was studied. CNS infection with Mycobacterium bovis Ravenel, M. bovis bacillus Calmette-Guerin (BCG) Pasteur, and M. bovis BCG Montreal were compared. M. bovis Ravenel induced the highest levels of TNF-alpha in the CSF in association with high leukocytosis, protein accumulation, and severe meningeal inflammation. BCG Pasteur had intermediate effects, and BCG Montreal was the least virulent. In addition, M. bovis Ravenel numbers were highest in the brain and CSF and the bacilli also disseminated more efficiently to distant organs, compared with BCG Pasteur and BCG Montreal. In subsequent experiments, rabbits were infected with either recombinant M. bovis BCG Montreal (vector), or BCG Montreal expressing the murine gene for TNF-alpha (BCG mTNF-alpha). BCG Montreal was rendered virulent by the expression of murine TNF-alpha, as demonstrated by high CSF leukocytosis, high protein accumulation, severe meningeal inflammation, persistent bacillary load, and progressive clinical deterioration. Taken together, these results demonstrate that the level of TNF-alpha produced during mycobacterial CNS infection determines, at least in part, the extent of pathogenesis. (+info)Cerebral malaria versus bacterial meningitis in children with impaired consciousness. (4/489)
Cerebral malaria (CM) and acute bacterial meningitis (ABM) are the two common causes of impaired consciousness in children presenting to hospital in sub-Sahara Africa. Since the clinical features of the two diseases may be very similar, treatment is often guided by the initial laboratory findings. However, no detailed studies have examined the extent to which the laboratory findings in these two diseases may overlap. We reviewed data from 555 children with impaired consciousness admitted to Kilifi District Hospital, Kenya. Strictly defined groups were established based on the malaria slide, cerebrospinal fluid (CSF) leucocyte count and the results of blood and CSF culture and CSF bacterial antigen testing. Our data suggests significant overlap in the initial CSF findings between CM and ABM. The absolute minimum proportions of children with impaired consciousness and malaria parasitaemia who also had definite bacterial meningitis were 4% of all children and 14% of children under 1 year of age. The estimated maximum proportion of all children with impaired consciousness and malaria parasitaemia in whom the diagnosis was dual or unclear was at least 13%. The finding of malaria parasites in the blood of an unconscious child in sub-Saharan Africa is not sufficient to establish a diagnosis of cerebral malaria, and acute bacterial meningitis must be actively excluded in all cases. (+info)Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. (5/489)
Bacterial meningitis is a disease worsened by neutrophil-induced damage in the subarachnoid space. In this study, the A2A adenosine receptors on human neutrophils were characterized, and the role of A2A receptors on the trafficking of leukocytes to the cerebrospinal fluid and on blood-brain barrier permeability (BBBP) was assessed in a rat meningitis model. Neutrophils bind the A2A selective antagonist, 125I-ZM241385 (Bmax=843 receptors/neutrophil; KD=0.125 nM). A selective A2A receptor agonist, WRC-0470 (2-cyclohexylmethylidene-hydrazinoadenosine; 0.03-1 microM), alone and synergistically with the type IV phosphodiesterase inhibitor, rolipram, increased neutrophil [cAMP]i and reduced cytokine-enhanced neutrophil adherence, superoxide release, and degranulation. These effects of WRC-0470 were reversed by ZM241385 (100 nM). In a lipopolysaccharide-induced rat meningitis model, WRC-0470 (0-0.9 microgram/kg/h), with or without rolipram (0-0.01 microgram/kg/h), inhibited pleocytosis and reduced the lipopolysaccharide-induced increase in BBBP, indicative of decreased neutrophil-induced damage. (+info)Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. (6/489)
Fifty-eight acute promyelocytic leukemia (APL) patients (11 newly diagnosed and 47 relapsed) were studied for arsenic trioxide (As2O3) treatment. Clinical complete remission (CR) was obtained in 8 of 11 (72.7%) newly diagnosed cases. However, As2O3 treatment resulted in hepatic toxicity in 7 cases including 2 deaths, in contrast to the mild liver dysfunction in one third of the relapsed patients. Forty of forty-seven (85.1%) relapsed patients achieved CR. Two of three nonresponders showed clonal evolution at relapse, with disappearance of t(15;17) and PML-RARalpha fusion gene in 1 and shift to a dominant AML-1-ETO population in another, suggesting a correlation between PML-RARalpha expression and therapeutic response. In a follow-up of 33 relapsed cases over 7 to 48 months, the estimated disease-free survival (DFS) rates for 1 and 2 years were 63.6% and 41.6%, respectively, and the actual median DFS was 17 months. Patients with white blood cell (WBC) count below 10 x 10(9)/L at relapse had better survival than those with WBC count over 10 x 10(9)/L (P =.038). The duration of As2O3-induced CR was related to postremission therapy, because there was only 2 of 11 relapses in patients treated with As2O3 combined with chemotherapy, compared with 12 of 18 relapses with As2O3 alone (P =.01). Reverse transcription polymerase chain reaction (RT-PCR) analysis in both newly diagnosed and relapsed groups showed long-term use of As2O3 could lead to a molecular remission in some patients. We thus recommend that ATRA be used as first choice for remission induction in newly diagnosed APL cases, whereas As2O3 can be either used as a rescue for relapsed cases or included into multidrug consolidation/maintenance clinical trials. (+info)Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. (7/489)
The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied. By either intravenous or oral administration, the drug was successful in reducing peripheral leukocyte and blast counts in all cases and in reducing splenomegaly in 13 of 17 patients. The median duration of disease control was 75 days in myeloproliferative acceleration and 27 days in frank blastic transformation. Mild nausea and vomiting were experienced by most patients, but reversible bone marrow suppression occured in only three patients. The drug proved useful in 19 patients who demonstrated myeloproliferative acceleration, especially in controlling excessive leukocytosis and/or thrombocytosis. Rapid reduction of an elevated blast cell count was achieved in nine patients who presented in blastic crisis, in an attempt to eliminate the associated risk of cerebral vascular leukostasis. Five patients who required treatment for their disease following splenectomy in the chronic phase were also well controlled. Hydroxyurea appears to have a definite role in the management of these hematologic complications of CGL. (+info)Epidemiological and clinical differences of snake bites among children and adults in south western Saudi Arabia. (8/489)
OBJECTIVES: To compare the clinical course and complications of snake bite in children and adults. METHODS: A retrospective review of 66 patients (28 children and 38 adults) admitted after snake bites for management at the Prince Abdullah Hospital in Bisha, in the south western part of Saudi Arabia, during the period May 1992 to May 1995. RESULTS: No significant difference was found in time of bite, site of bite, and sex preference between adults and children. Local complications, such as tissue necrosis, were commoner in children (14%) than in adults (5%). Systemic manifestations were also more commonly seen in children than in adults; this is possibly due to a higher ratio of injected venom to body mass in children. Leukocytosis was seen in 54% of children (adults 13%), a low haemoglobin concentration in 14% of children (adults 11%), prolonged prothrombin and partial thromboplastin times in 41% of children (adults 16%), while a high creatine phosphokinase was seen in 31% of children compared with 17% of adults. CONCLUSIONS: Children seem to have more serious local and systemic complications than adults and this may indicate the need to use a higher dose of antivenom than that being used at present. (+info)White blood cells are an important part of the immune system and play a crucial role in fighting off infections and diseases. However, when there is an excessive increase in their numbers, it can lead to various complications, including:
1. Increased risk of infection: With too many white blood cells in the bloodstream, there is a higher chance of developing infections.
2. Inflammation: Excessive production of white blood cells can cause inflammation in various parts of the body.
3. Blood clotting disorders: White blood cells can clump together and form clots, which can lead to blockages in blood vessels.
4. Tissue damage: The excessive growth of white blood cells can cause damage to tissues and organs.
5. Bone marrow failure: Prolonged leukocytosis can lead to bone marrow failure, which can result in a decrease in the production of other blood cells, such as red blood cells and platelets.
There are several types of leukocytosis, including:
1. Reactive leukocytosis: This is the most common type and is caused by an infection or inflammation.
2. Chronic leukocytosis: This type is characterized by a persistent increase in white blood cells over a long period of time.
3. Acute leukocytosis: This type is characterized by a sudden and severe increase in white blood cells, often accompanied by other symptoms such as fever and fatigue.
4. Leukemia: This is a type of cancer that affects the bone marrow and blood cells. It can cause an abnormal increase in white blood cells.
Diagnosis of leukocytosis typically involves a physical examination, medical history, and laboratory tests such as complete blood count (CBC) and bone marrow biopsy. Treatment depends on the underlying cause and may include antibiotics for infections, steroids to reduce inflammation, or chemotherapy for leukemia. In some cases, no treatment is necessary if the condition resolves on its own.
Leukemoid reactions can occur as a result of various conditions, such as:
1. Infections: Certain infections like HIV, TB, and other bacterial and viral infections can trigger an overactive immune response, leading to the production of excessive white blood cells.
2. Allergic reactions: Severe allergic reactions can cause the body to produce a large number of white blood cells, which can lead to a leukemoid reaction.
3. Autoimmune disorders: Conditions like rheumatoid arthritis, lupus, and other autoimmune diseases can cause the immune system to attack healthy tissues, leading to the production of excessive white blood cells.
4. Cancer: In some cases, certain types of cancer can cause a leukemoid reaction due to the excessive production of white blood cells.
5. Genetic disorders: Certain genetic disorders like myeloproliferative neoplasms and myelodysplastic syndrome can also lead to a leukemoid reaction.
The symptoms of a leukemoid reaction are similar to those of leukemia, including fatigue, fever, night sweats, weight loss, and an enlarged spleen. However, unlike leukemia, the white blood cell count is usually not as high in cases of leukemoid reactions.
Treatment for a leukemoid reaction depends on the underlying cause. In some cases, treatment may involve addressing the underlying condition, such as managing an infection or autoimmune disorder. In other cases, medications may be used to reduce inflammation and suppress the immune system. In rare cases, a bone marrow transplant may be necessary.
In summary, a leukemoid reaction is a condition where there is an excessive accumulation of white blood cells in the body, which can mimic leukemia. The causes of a leukemoid reaction are diverse and include infections, autoimmune disorders, allergies, and certain types of cancer or genetic disorders. Treatment depends on the underlying cause and may involve addressing the underlying condition, using medications to reduce inflammation and suppress the immune system, or in rare cases, a bone marrow transplant.
The term "paraneoplastic" refers to the fact that these conditions are parallel to, or associated with, neoplasms (abnormal growths) in the body. The exact cause of paraneoplastic syndromes is not fully understood, but they are believed to be related to the immune system's response to cancer cells.
Some common features of paraneoplastic syndromes include:
1. Autoantibodies: The immune system produces antibodies that attack the body's own tissues and organs.
2. Inflammation: The immune system causes inflammation in various parts of the body.
3. Nerve damage: Paraneoplastic syndromes can affect the nerves, leading to symptoms such as numbness, weakness, and pain.
4. Muscle weakness: Some paraneoplastic syndromes can cause muscle weakness and wasting.
5. Skin rashes: Some patients with paraneoplastic syndromes may develop skin rashes or lesions.
6. Eye problems: Paraneoplastic syndromes can affect the eyes, leading to symptoms such as double vision, blindness, and eye pain.
7. Endocrine dysfunction: Some paraneoplastic syndromes can disrupt the normal functioning of the endocrine system, leading to hormonal imbalances.
Examples of paraneoplastic syndromes include:
1. Lambert-Eaton myasthenic syndrome (LEMS): This is a rare autoimmune disorder that affects the nerves and muscles, leading to muscle weakness and fatigue. It is often associated with small cell lung cancer.
2. Anti-NMDA receptor encephalitis: This is a severe autoimmune disorder that affects the brain and can cause symptoms such as seizures, confusion, and memory loss. It is often associated with ovarian teratoma.
3. Paraneoplastic cerebellar degeneration (PCD): This is a rare condition that affects the cerebellum and can cause symptoms such as coordination problems, balance difficulties, and difficulty with movement. It is often associated with lung cancer or other types of cancer.
4. Stiff-person syndrome: This is a rare autoimmune disorder that affects the central nervous system and can cause symptoms such as muscle stiffness, spasms, and autonomy dysfunction. It is often associated with ovarian teratoma.
5. Polymyositis: This is a rare inflammatory condition that affects the muscles and can cause muscle weakness and wasting. It is often associated with cancer, particularly lung cancer.
6. Dercum's disease: This is a rare condition that affects the adipose tissue and can cause symptoms such as pain, swelling, and limited mobility. It is often associated with cancer, particularly breast cancer.
7. Multiple myeloma: This is a type of cancer that affects the plasma cells in the bone marrow and can cause symptoms such as bone pain, fatigue, and weakness. It is often associated with ovarian teratoma.
8. Painless thyroiditis: This is a rare condition that affects the thyroid gland and can cause symptoms such as thyroid gland inflammation, fatigue, and weight gain. It is often associated with cancer, particularly breast cancer.
9. Ovarian cysts: These are fluid-filled sacs that form on the ovaries and can cause symptoms such as pelvic pain, bloating, and irregular menstrual periods. They are often associated with ovarian teratoma.
10. Endometriosis: This is a condition in which tissue similar to the lining of the uterus grows outside of the uterus and can cause symptoms such as pelvic pain, heavy menstrual bleeding, and infertility. It is often associated with ovarian teratoma.
It's important to note that these conditions are rare and not all cases of ovarian teratoma are associated with them. If you suspect you may have ovarian teratoma, it's important to talk to your healthcare provider for proper diagnosis and treatment.
In healthy individuals, the normal platelet count ranges from 150,000 to 450,000 platelets per microliter of blood. In thrombocytosis, the platelet count is significantly higher than this range, often above 600,000 platelets/μL.
Thrombocytosis can be caused by a variety of factors, including:
1. Bone marrow disorders: Disorders such as essential thrombocythemia, polycythemia vera, and myelofibrosis can lead to an overproduction of platelets in the bone marrow.
2. Infection: Sepsis and other infections can cause a temporary increase in platelet production.
3. Inflammation: Certain inflammatory conditions, such as appendicitis and pancreatitis, can also lead to thrombocytosis.
4. Cancer: Some types of cancer, such as leukemia and lymphoma, can cause an overproduction of platelets.
5. Medications: Certain medications, such as estrogens and corticosteroids, can increase platelet production.
Thrombocytosis can lead to a range of complications, including:
1. Blood clots: The excessive number of platelets in the blood can increase the risk of blood clots forming in the veins and arteries.
2. Pulmonary embolism: If a blood clot forms in the lungs, it can cause a pulmonary embolism, which can be life-threatening.
3. Stroke: Thrombocytosis can increase the risk of stroke, especially if there are existing risk factors such as high blood pressure or a history of cardiovascular disease.
4. Heart attack and heart failure: Excessive platelet activity can increase the risk of heart attack and heart failure.
5. Gastrointestinal bleeding: The increased number of platelets in the blood can make it more difficult to control bleeding, especially in the gastrointestinal tract.
Thrombocytosis is typically diagnosed through a combination of physical examination, medical history, and laboratory tests, such as:
1. Complete blood count (CBC): This test measures the number of platelets in the blood, as well as other components such as red and white blood cells.
2. Blood smear: A sample of blood is examined under a microscope to assess the shape and size of the platelets.
3. Bone marrow aspiration and biopsy: These tests involve removing a small sample of bone marrow tissue to examine the number and type of cells present.
4. Imaging studies: Imaging tests such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) may be used to look for evidence of blood clots or other complications.
Treatment for thrombocytosis depends on the underlying cause and the severity of the condition. Some common treatments include:
1. Medications: Drugs such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and blood thinners may be used to reduce the risk of blood clots and other complications.
2. Plateletpheresis: This is a procedure in which the patient's blood is removed and the platelets are separated from the rest of the blood components. The remaining blood is then returned to the body.
3. Splenectomy: In some cases, surgical removal of the spleen may be necessary to treat thrombocytosis.
4. Chemotherapy: This is a treatment that uses drugs to kill cancer cells, which can cause thrombocytosis in some cases.
Overall, it is important to seek medical attention if you experience any symptoms of thrombocytosis, as early diagnosis and treatment can help prevent complications and improve outcomes.
1. Primary essential thrombocythemia (PET): This is the more common form, usually occurring spontaneously without any identifiable cause. Symptoms may include headache, migraine, seizures, and stroke-like episodes.
2. Secondary essential thrombocythemia: This form is caused by another medical condition or medication that stimulates the production of platelets. Symptoms are similar to those of PET, but there may be an underlying cause such as a tumor or an adverse reaction to medication.
Treatment for essential thrombocythemia includes medications to reduce platelet count and prevent blood clots, as well as close monitoring and management of any underlying causes. In some cases, surgery may be necessary to remove a tumor or other contributing factor.
The exact cause of polycythemia vera is not known, but it is believed to be due to a genetic mutation in the JAK2 gene, which is involved in the signaling pathways that regulate blood cell production. The condition typically affects adults over the age of 60 and is more common in men than women.
Symptoms of polycythemia vera can include:
* Fatigue
* Weakness
* Shortness of breath
* Headaches
* Dizziness
* Itching
* Night sweats
* Weight loss
Diagnosis of polycythemia vera is typically made based on a combination of physical examination, medical history, and laboratory tests, including:
* Complete blood count (CBC) to measure the levels of red blood cells, white blood cells, and platelets
* Blood chemistry tests to assess liver function and other body chemicals
* Genetic testing to look for the JAK2 mutation
* Bone marrow biopsy to examine the bone marrow tissue for abnormalities
Treatment for polycythemia vera usually involves phlebotomy (the removal of blood from the body) to reduce the number of red blood cells and relieve symptoms such as itching and night sweats. In some cases, medications may be used to reduce the production of blood cells or to treat specific symptoms. Regular monitoring by a healthcare provider is important to detect any changes in the condition and to prevent complications.
Overall, polycythemia vera is a chronic and progressive disease that can have significant impact on quality of life if left untreated. Early diagnosis and appropriate treatment can help manage symptoms and improve outcomes for patients with this condition.
The symptoms of hypercalcemia may include:
* Fatigue
* Nausea and vomiting
* Weakness
* Constipation
* Abdominal pain
* Kidney stones
* Bone pain or fractures
If left untreated, hypercalcemia can lead to complications such as kidney damage, heart problems, and an increased risk of osteoporosis. Treatment options may include medications to reduce calcium levels, surgery to remove a tumor or overactive parathyroid gland, or dialysis if the patient has kidney failure.
Early diagnosis and treatment are important to prevent long-term complications and improve the patient's quality of life.
The term splenomegaly is used to describe any condition that results in an increase in the size of the spleen, regardless of the underlying cause. This can be caused by a variety of factors, such as infection, inflammation, cancer, or genetic disorders.
Splenomegaly can be diagnosed through a physical examination, where the doctor may feel the enlarged spleen during an abdominal palpation. Imaging tests, such as ultrasound, computed tomography (CT) scans, or magnetic resonance imaging (MRI), may also be used to confirm the diagnosis and evaluate the extent of the splenomegaly.
Treatment for splenomegaly depends on the underlying cause. For example, infections such as malaria or mononucleosis are treated with antibiotics, while cancerous conditions may require surgical intervention or chemotherapy. In some cases, the spleen may need to be removed, a procedure known as splenectomy.
In conclusion, splenomegaly is an abnormal enlargement of the spleen that can be caused by various factors and requires prompt medical attention for proper diagnosis and treatment.
There are several possible causes of lymphocytosis, including:
1. Infection: Lymphocytosis can be caused by a variety of infections, such as viral or bacterial infections.
2. Autoimmune disorders: Conditions such as rheumatoid arthritis, lupus, and multiple sclerosis can cause an abnormal increase in lymphocytes.
3. Cancer: Lymphocytosis can be a symptom of certain types of cancer, such as Hodgkin's disease and non-Hodgkin's lymphoma.
4. Reaction to medication: Certain medications, such as antibiotics and chemotherapy drugs, can cause lymphocytosis.
5. Genetic disorders: Certain genetic disorders, such as X-linked agammaglobulinemia, can cause lymphocytosis.
Symptoms of lymphocytosis may include swollen lymph nodes, fatigue, fever, and weight loss. Treatment depends on the underlying cause of the condition, and may involve antibiotics, chemotherapy, or other medications. In some cases, no treatment is necessary, as the condition may resolve on its own over time.
There are several types of MPDs, including:
1. Polycythemia vera (PV): This is a rare disorder characterized by an overproduction of red blood cells, white blood cells, and platelets.
2. Essential thrombocythemia (ET): This is a rare disorder characterized by an overproduction of platelets.
3. Primary myelofibrosis (PMF): This is a rare and severe disorder characterized by the accumulation of scar tissue in the bone marrow, leading to an overproduction of immature white blood cells.
4. Chronic myelogenous leukemia (CML): This is a type of cancer that affects the bone marrow and blood cells, characterized by the overproduction of immature white blood cells.
The symptoms of MPDs can vary depending on the specific disorder, but may include:
* Fatigue
* Weakness
* Shortness of breath
* Headaches
* Dizziness
* Pale skin
* Easy bruising or bleeding
* Swollen spleen
* Bone pain
The exact cause of MPDs is not known, but they are thought to be due to genetic mutations that occur in the bone marrow cells. Treatment options for MPDs include:
* Chemotherapy: This is a type of drug that kills cancer cells.
* Radiation therapy: This is a type of treatment that uses high-energy X-rays to kill cancer cells.
* Stem cell transplantation: This is a procedure in which healthy stem cells are transplanted into the body to replace damaged or diseased bone marrow cells.
Overall, MPDs are rare and complex disorders that can have a significant impact on quality of life. While there is no cure for these conditions, treatment options are available to help manage symptoms and improve outcomes.
A type of anemia that is caused by a deficiency of red blood cells and bone marrow due to damage to the bone marrow. It is often seen in people with chronic diseases such as rheumatoid arthritis, cancer, and HIV/AIDS.
Symptoms include fatigue, weakness, pale skin, and shortness of breath. Treatment options include blood transfusions and medications to stimulate red blood cell production.
Sources:
* Merck Manual, 20th edition
* National Heart, Lung, and Blood Institute
* American Society of Hematology
Note: This definition is a summary and may not include all possible information or uses of the term "anemia, myelophthisic."
Example sentences:
1. The patient was diagnosed with diverticulitis, colonic, and was admitted to the hospital for further treatment.
2. The doctor recommended a high-fiber diet and antibiotics to treat the diverticulitis, colonic, and prevent future complications.
3. The patient experienced severe abdominal pain due to diverticulitis, colonic, and required surgical intervention to repair the damaged tissue.
PMF is a chronic disease that worsens over time, and it can lead to complications such as bleeding, infection, and bone damage. Treatment options include medications to reduce symptoms and slow the progression of the disease, as well as blood transfusions and splenectomy (removal of the spleen) in severe cases. The median age at diagnosis is around 60 years old, and the disease affects approximately 2-5 cases per million people per year.
Sources:
* American Cancer Society. (2019). What is primary myelofibrosis? Retrieved from
* Leukemia and Lymphoma Society. (n.d.). Primary Myelofibrosis. Retrieved from
There are different types of fever, including:
1. Pyrexia: This is the medical term for fever. It is used to describe a body temperature that is above normal, usually above 38°C (100.4°F).
2. Hyperthermia: This is a more severe form of fever, where the body temperature rises significantly above normal levels.
3. Febrile seizure: This is a seizure that occurs in children who have a high fever.
4. Remittent fever: This is a type of fever that comes and goes over a period of time.
5. Intermittent fever: This is a type of fever that recurs at regular intervals.
6. Chronic fever: This is a type of fever that persists for an extended period of time, often more than 3 weeks.
The symptoms of fever can vary depending on the underlying cause, but common symptoms include:
* Elevated body temperature
* Chills
* Sweating
* Headache
* Muscle aches
* Fatigue
* Loss of appetite
In some cases, fever can be a sign of a serious underlying condition, such as pneumonia, meningitis, or sepsis. It is important to seek medical attention if you or someone in your care has a fever, especially if it is accompanied by other symptoms such as difficulty breathing, confusion, or chest pain.
Treatment for fever depends on the underlying cause and the severity of the symptoms. In some cases, medication such as acetaminophen (paracetamol) or ibuprofen may be prescribed to help reduce the fever. It is important to follow the recommended dosage instructions carefully and to consult with a healthcare professional before giving medication to children.
In addition to medication, there are other ways to help manage fever symptoms at home. These include:
* Drinking plenty of fluids to stay hydrated
* Taking cool baths or using a cool compress to reduce body temperature
* Resting and avoiding strenuous activities
* Using over-the-counter pain relievers, such as acetaminophen (paracetamol) or ibuprofen, to help manage headache and muscle aches.
Preventive measures for fever include:
* Practicing good hygiene, such as washing your hands frequently and avoiding close contact with people who are sick
* Staying up to date on vaccinations, which can help prevent certain infections that can cause fever.
The symptoms of Sweet syndrome typically begin with a high fever, usually over 101°F (38.3°C), and are often accompanied by headache, muscle aches, and fatigue. Within 24 to 48 hours, a red rash appears on the skin, typically on the extremities, trunk, and face. The rash is made up of small, painful bumps or papules that may develop into pustules or blisters.
Sweet syndrome is caused by an abnormal immune response, which leads to an overproduction of neutrophils in the blood. Neutrophils are a type of white blood cell that plays a crucial role in fighting off bacterial infections. However, in Sweet syndrome, the excessive production of neutrophils causes inflammation and damage to the skin and other tissues.
The exact cause of Sweet syndrome is not known, but it is believed to be triggered by a variety of factors, including infections, medications, cancer, and autoimmune disorders. The condition is more common in adults than children and is rare in people over the age of 60.
Sweet syndrome can be challenging to diagnose, as it can resemble other skin conditions such as psoriasis or eczema. A diagnosis is typically made based on a combination of physical examination, medical history, and laboratory tests, including blood counts and skin scrapings.
Treatment for Sweet syndrome usually involves the use of antibiotics to control any underlying infections, as well as medications to reduce inflammation and suppress the overproduction of neutrophils. In severe cases, hospitalization may be necessary to manage the condition.
The prognosis for Sweet syndrome is generally good, with most people experiencing a full recovery within a few weeks or months. However, in some cases, the condition can persist or recur, and there is a risk of complications such as scarring or skin thickening.
There are several ways to manage Sweet syndrome and reduce the risk of complications, including:
1. Avoiding triggers: Identifying and avoiding any triggers that may be causing the condition can help prevent flare-ups.
2. Keeping the skin clean: Proper skin care and hygiene can help prevent infection and reduce inflammation.
3. Using topical medications: Over-the-counter or prescription creams, ointments, or patches can be applied directly to the affected area to reduce inflammation and suppress neutrophil production.
4. Taking antibiotics: If an underlying infection is suspected, antibiotics may be prescribed to treat the infection and prevent it from spreading.
5. Managing stress: Stress can exacerbate Sweet syndrome, so finding ways to manage stress, such as through exercise, meditation, or therapy, can be helpful.
6. Seeking medical attention: If symptoms persist or worsen over time, it is important to seek medical attention to rule out any underlying conditions that may need to be treated.
It is important to note that Sweet syndrome is a relatively rare condition and can be challenging to diagnose. A healthcare professional should be consulted for proper evaluation and treatment. With appropriate management, most people with Sweet syndrome can experience improvement in their symptoms and quality of life.
Leukocytosis
Febrile neutrophilic dermatosis
Atypical pneumonia
Granulocytosis
Chronic myelomonocytic leukemia
Prednisone
Left shift (medicine)
Pericoronitis
Tubo-ovarian abscess
Monocytosis
Hospital-acquired pneumonia
Epiploic appendagitis
Hemangiosarcoma
Leukostasis
Complete blood count
Geotrichosis
Leukemoid reaction
Visceral larva migrans
Infectious mononucleosis
Orthognathic surgery
Well-being contributing factors
Appendicitis
Nanocovax
Radiculopathy
Eosinopenia
Biloma
Reactive lymphocyte
Sciatica
Ulcerative colitis
Eucestoda
Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity - Volume 26, Number 8-August 2020 - Emerging...
BestBets: Leukocytosis as a predictor for progression to haemolytic uraemic syndrome in Escherichia coli O157:H7 infection
Aricept and Leukocytosis, a phase IV clinical study of FDA data - eHealthMe
A 42-year-old farmer with nonspecific leucocytosis and elevated transaminases. Acute septic reaction in Coxiella burnetii...
These highlights do not include all the information needed to use ZIEXTENZO safely and effectively. See full prescribing...
Subjects: Leukocytosis -- blood - Digital Collections - National Library of Medicine Search Results
Practice Perfect 845 - Postoperative Leukocytosis - A Common but Unreliable Indicator of Infection
Emergency Response Safety and Health Database: Glossary | NIOSH | CDC
Leucocytosis is associated with retinopathy of prematurity in extremely preterm infants. | Acta Paediatr;108(7): 1357-1358,...
INTERNAL MEDICINE | MindMeister Mind Map
Hyperkalemia in Emergency Medicine Clinical Presentation: History, Physical, Causes
LCD - Urological Supplies (L33803)
Schnitzler Syndrome Workup: Approach Considerations, Laboratory Studies, Imaging Studies
Cholinesterase Inhibitors: Part 4: The Cholinergic Toxidrome Section 7: Differential Diagnosis of the Cholinergic Toxidrome |...
NYPH-WMC's Pediatric Oncology Service | Memorial Sloan Kettering Cancer Center
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers - Study...
T-cell count: MedlinePlus Medical Encyclopedia
Hyperkalemia | AAFP
Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis): Practice Essentials, Background, Etiology
Ethylene Dibromide | Medical Management Guidelines | Toxic Substance Portal | ATSDR
David M. Mintzer, MD profile | PennMedicine.org
AIDS-04 - Technical Report on the Reproductive, Developmental, and General Toxicity Study of 3'-Azido-3'-deoxythymidine (AZT)...
CDC | Toxic Syndrome Description: Ricin or Abrin Poisoning
Biochemistry (1971-75)
Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis): Practice Essentials, Background, Etiology
DailyMed - VENLAFAXINE HYDROCHLORIDE- venlafaxine tablet, extended release
Shawn R. Simonson - Search Results - PubMed
Thrombocytosis1
- CBC with differrntial and platelets: Leukocytosis (70%), thrombocytosis (20%), and anemia (50%) may be found. (medscape.com)
Neutrophilic1
- Abnormalities on CBC are usually limited to hemoconcentration and neutrophilic leukocytosis. (merckvetmanual.com)
Fever2
- We expect to see rapid improvement in the indicators of infection, most commonly a decrease in fever and a declining leukocytosis. (podiatry.com)
- As a lover of medical history, I cannot help but point out that we use so many of these words, such as fever and leukocytosis, never thinking about those who came before. (podiatry.com)
Elevation1
- We report about a 42-year-old farmer with leucocytosis, elevation of transaminases and liver cirrhosis as an underlying condition. (nih.gov)
Acute1
- Leukocytosis is relatively common in dogs with acute pancreatitis. (vin.com)
Absence1
- Concludes absence of leukocytosis indicates very low risk for HUS. (bestbets.org)
White cell1
- Addition of the key words (leukocytosis OR "white cell count") to the above yielded only seven results. (bestbets.org)
Blood2
- Leukocytosis (increased white blood cells) is found to be associated with 2,251 drugs and 1,734 conditions by eHealthMe. (ehealthme.com)
- Blood work was significant for mild leukocytosis. (emra.org)
Results1
- Is postoperative leukocytosis something to be concerned about or is there a more nuanced way to interpret these test results? (podiatry.com)
Studies3
- Although many ongoing studies are investigating measurement of proinflammatory cytokines and other biomarkers as a way to prognosticate infection severity, we investigated use of 2 easily obtained predictors: lymphopenia and leukocytosis ( 3 ). (cdc.gov)
- The vast majority of research studies show that postoperative leukocytosis is physiologic and not an indicator of infection. (podiatry.com)
- One commonality with these studies was the significance of the two-day timeframe at which one may expect postoperative Leukocytosis but after which it was an indicator of infection. (podiatry.com)
Increase1
- Leukocytosis is an increase above the accepted normal range of total leukocytes. (ndtv.com)